Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ. The company's Chief Financial & Business Officer, Bart van Rhijn, will participate in a fireside chat on Tuesday, May 20, 2025, at 5:00 pm EDT in New York. The presentation will be webcast live and available for replay on the company's investor relations website.
Nanobiotix (NASDAQ: NBTX), un'azienda biotecnologica in fase clinica avanzata specializzata in trattamenti oncologici a base di nanoparticelle, ha annunciato la sua partecipazione alla 3陋 Conferenza Annuale BioConnect per Investitori di H.C. Wainwright presso il NASDAQ. Il Chief Financial & Business Officer dell'azienda, Bart van Rhijn, prender脿 parte a una conversazione informale il marted矛 20 maggio 2025 alle 17:00 EDT a New York. La presentazione sar脿 trasmessa in diretta streaming e sar脿 disponibile per la visione on demand sul sito web delle relazioni con gli investitori dell'azienda.
Nanobiotix (NASDAQ: NBTX), una empresa biotecnol贸gica en etapa cl铆nica avanzada enfocada en tratamientos contra el c谩ncer basados en nanopart铆culas, anunci贸 su participaci贸n en la 3陋 Conferencia Anual BioConnect para Inversionistas de H.C. Wainwright en NASDAQ. El Director Financiero y de Negocios de la compa帽铆a, Bart van Rhijn, participar谩 en una charla informal el martes 20 de mayo de 2025 a las 5:00 pm EDT en Nueva York. La presentaci贸n ser谩 transmitida en vivo por internet y estar谩 disponible para su reproducci贸n en el sitio web de relaciones con inversionistas de la empresa.
Nanobiotix (NASDAQ: NBTX)電� 雮橂吀鞛呾瀽 旮半皹 鞎� 旃橂鞐� 欷戩爯鞚� 霊� 頉勱赴 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 須岇偓搿�, NASDAQ鞐愳劀 鞐措Μ電� H.C. Wainwright 鞝�3須� 鞐半 BioConnect 韴瀽鞛� 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� 斓滉碃鞛毂呾瀯鞛� 瓴� 靷梾毂呾瀯鞛愳澑 Bart van Rhijn鞚� 2025雲� 5鞗� 20鞚� 頇旍殧鞚� 鞓ろ泟 5鞁�(EDT) 雺挫殨鞐愳劀 鞐措Μ電� 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳棳頃� 鞓堨爼鞛呺媹雼�. 氚滍憸電� 鞁れ嫓臧� 鞗轨簮鞀ろ姼搿� 欷戧硠霅橂┌ 須岇偓鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐愳劀 雼れ嫓氤搓赴搿� 鞝滉车霅╇媹雼�.
Nanobiotix (NASDAQ : NBTX), une soci茅t茅 biotechnologique en phase clinique avanc茅e sp茅cialis茅e dans les traitements du cancer 脿 base de nanoparticules, a annonc茅 sa participation 脿 la 3e Conf茅rence Annuelle BioConnect pour Investisseurs de H.C. Wainwright au NASDAQ. Le Directeur Financier et des Affaires de la soci茅t茅, Bart van Rhijn, participera 脿 une discussion informelle le mardi 20 mai 2025 脿 17h00 EDT 脿 New York. La pr茅sentation sera diffus茅e en direct sur le web et disponible en replay sur le site des relations investisseurs de la soci茅t茅.
Nanobiotix (NASDAQ: NBTX), ein Biotechnologieunternehmen in der sp盲ten klinischen Phase, das sich auf nanopartikelbasierte Krebsbehandlungen spezialisiert hat, gab seine Teilnahme an der 3. j盲hrlichen BioConnect Investorenkonferenz von H.C. Wainwright am NASDAQ bekannt. Der Finanz- und Gesch盲ftsdirektor des Unternehmens, Bart van Rhijn, wird an einem Gespr盲ch am Kamin am Dienstag, den 20. Mai 2025, um 17:00 Uhr EDT in New York teilnehmen. Die Pr盲sentation wird live im Webcast 眉bertragen und auf der Investor-Relations-Website des Unternehmens zur Wiederholung verf眉gbar sein.
- None.
- None.
PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO 鈥撯�� NASDAQ: NBTX 鈥� the 鈥樷��Company鈥欌��), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference:
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Date: Tuesday, May 20, 2025
Time: 5:00听pm EDT / 11:00听pm CEST
Location: New York, NY
Presenters: Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link:
The fireside chats will be webcast live from the of the Investors section of the Company鈥檚 website. The replay of the webcast will be available following the event.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company鈥檚 philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at or follow us on and
Contacts
| Nanobiotix | 听 | |||
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 [email protected] | Investor Relations Department Ricky Bhajun Director, Investor Relations +33 (0)6 42 05 34 15 [email protected] | 听 | ||
| Media Relations | 听 | |||
France 鈥� HARDY Caroline Hardy +33 06 70 33 49 50 [email protected] | Global 鈥� uncapped Becky Lauer +1 (646) 286-0057 [email protected] | 听 | ||
Attachments
- -- Presenting @ HCW&Co -- FINAL
FAQ
When is Nanobiotix (NBTX) presenting at the H.C. Wainwright BioConnect Conference 2025?
Who will represent Nanobiotix (NBTX) at the H.C. Wainwright Conference 2025?
What type of company is Nanobiotix (NBTX)?
How can investors watch Nanobiotix's (NBTX) presentation at the H.C. Wainwright Conference?
